The FDA has approved the drug facility of Strides Arcolab's Italian unit Beltapharm in Milan, allowing the company to enter the U.S. semisolid market. The facility will produce creams, ointments, semisolids and liquids, the drugmaker said in a statement. The facility is already cleared in Australia and the European Union.

Full Story:
BioSpectrum Asia

Related Summaries